A medicine developed by the American pharmaceutical Sorrento Tehrapeutics to treat people who have contracted COVID-19 will be tested with patients in Rio de Janeiroannounced the mayor of this Brazilian city.
The clinical trials of the hopeful treatment with patients admitted to hospitals in Rio de Janeiro, whose first tests were successful, will be possible thanks to a cooperation agreement that the Rio de Janeiro mayor’s office signed with Sorrento, according to a statement from the municipality.
Medicine, a antibody cocktail, it has already been tested in patients from other countries “with a good outcome perspective in the treatment of patients with COVID “, informed the mayor of Rio de Janeiro.
According to the municipality, the agreement does not imply any cost for the mayor’s office, but the start of the experiments still depends on the National Health Surveillance Agency (Anvisa, regulator) approve the use of the medicine in Brazil, as well as the approval of the Ethics Committee in Studies of the Municipal Health Secretariat.
Once the authorizations have been received, the mayor’s office will select patients with COVID-19 who accept the treatment voluntarily, for which they will have to sign a consent term.
“Those selected for the clinical study will be patients already diagnosed with the disease. The number of people who will participate in the medicine experiments has not yet been defined., which is a cocktail of antibodies that can neutralize the coronavirus, “according to the mayor’s statement.
According to the Municipal Secretary of Health of Rio de Janeiro, Beatriz Busch, the agreement generates hope for people who have already contracted COVID. “I think it is something revolutionary. Is a hope“, he claimed.
The results of laboratory tests with the medicine were released last May and demonstrated the efficacy of the product for neutralize the disease in patients who have already contracted it, according to Sorrento Therapeutics.
According to the laboratory, antibody cocktail inhibits virus infection within four days.
The announcement by the Rio de Janeiro mayor’s office comes a day after Anvisa, a body linked to the Ministry of Health, approved the start of the clinical trials in Brazil of a new vaccine against COVID-19, the fourth experienced in the country against the virus.
The multinational Johnson & Johnson received authorization to test its vaccine in phase three clinical studies (with thousands of people), which is already done in Brazil with vaccines developed by the United Kingdom (AstraZeneca and University of Oxford), China (Sinovac Biotech) and by the consortium BioNTech (Germany) and Wyeth/Pfizer (U.S).
Brazil, where the coronavirus already leaves about 110,000 dead and 3.4 million infected, which makes it the second country most affected by the pandemic in the world after the United States, has become a benchmark for clinical trials of vaccines and medicines against the disease.
With about 210 million inhabitants and the high number of cases, the South American giant is the ideal laboratory for testing various potential vaccines, who are now looking to verify its efficacy and safety.